Skip to main content
Journal cover image

Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference.

Publication ,  Journal Article
Edmonston, DL; Roe, MT; Block, G; Conway, PT; Dember, LM; DiBattiste, PM; Greene, T; Hariri, A; Inker, LA; Isakova, T; Montez-Rath, ME ...
Published in: Am J Kidney Dis
December 2020

Occasional bursts of discovery and innovation have appeared during the otherwise stagnant past several decades of drug development in nephrology. Among other recent drug discoveries, the unexpected kidney benefits observed with sodium/glucose cotransporter 2 inhibitors may herald a renaissance of drug development in kidney disease. This recent progress highlights the need to further promote and stimulate research and development of promising therapies that may ameliorate the morbidity and mortality associated with kidney disease. To help identify and address barriers to drug development in nephrology, the Duke Clinical Research Institute convened a conference in April 2019 that included stakeholders from academia, industry, government agencies, and patient advocacy. From these discussions, several opportunities were identified to improve every stage of drug development for kidney disease from early discovery to implementation into practice. Key topics reviewed in this article are the utility of interconnected data and site research networks, surrogate end points, pragmatic and adaptive trial designs, the promising uses of real-world data, and methods to improve the generalizability of trial results and uptake of approved drugs for kidney-related diseases.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Kidney Dis

DOI

EISSN

1523-6838

Publication Date

December 2020

Volume

76

Issue

6

Start / End Page

842 / 850

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Research Design
  • Kidney Diseases
  • Humans
  • Drug Development
  • Drug Approval
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Edmonston, D. L., Roe, M. T., Block, G., Conway, P. T., Dember, L. M., DiBattiste, P. M., … Wolf, M. (2020). Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. Am J Kidney Dis, 76(6), 842–850. https://doi.org/10.1053/j.ajkd.2020.05.026
Edmonston, Daniel L., Matthew T. Roe, Geoffrey Block, Paul T. Conway, Laura M. Dember, Peter M. DiBattiste, Tom Greene, et al. “Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference.Am J Kidney Dis 76, no. 6 (December 2020): 842–50. https://doi.org/10.1053/j.ajkd.2020.05.026.
Edmonston DL, Roe MT, Block G, Conway PT, Dember LM, DiBattiste PM, et al. Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. Am J Kidney Dis. 2020 Dec;76(6):842–50.
Edmonston, Daniel L., et al. “Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference.Am J Kidney Dis, vol. 76, no. 6, Dec. 2020, pp. 842–50. Pubmed, doi:10.1053/j.ajkd.2020.05.026.
Edmonston DL, Roe MT, Block G, Conway PT, Dember LM, DiBattiste PM, Greene T, Hariri A, Inker LA, Isakova T, Montez-Rath ME, Nkulikiyinka R, Polidori D, Roessig L, Tangri N, Wyatt C, Chertow GM, Wolf M. Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. Am J Kidney Dis. 2020 Dec;76(6):842–850.
Journal cover image

Published In

Am J Kidney Dis

DOI

EISSN

1523-6838

Publication Date

December 2020

Volume

76

Issue

6

Start / End Page

842 / 850

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Research Design
  • Kidney Diseases
  • Humans
  • Drug Development
  • Drug Approval
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences